CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
canagliflozin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02673138
NCT02673138N/ACompleted
CompareCT.gov

Effect of Canagliflozin in T1DM After Interruption of Continuous Subcutaneous Insulin Infusion

Yale University·interventional·Posted Feb 3, 2016·Updated Oct 13, 2021

In Brief

A clinical study evaluating canagliflozin and basal interruption without canagliflozin for Type 1 Diabetes. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This study will be an open-label, cross-over study as subjects will be studied under both study conditions - suspension of subcutaneous insulin infusion via pump during treatment with insulin alone (control) vs. suspension of subcutaneous insulin via pump during treatment with insulin and canagliflozin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 3, 2016
Enrollment StartJan 1, 2016
Primary CompletionJan 1, 2017
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.4 years ago

Interventions

canagliflozindrug

basal interruption with canagliflozin

basal interruption without canagliflozinother

basal interruption